MeiraGTx Holdings plc, a gene therapy company, has raised $75 million for its IPO after pricing its 5 million shares at $15 per share. The stock began trading June 8, 2018 on the NASDAQ under the ticker symbol “MGTX.” BofA Merrill Lynch, Barclays and Evercore ISI are the lead underwriters. MeiraGTx’s pre-IPO backers include Essex Bio-Technology, according to Crunchbase.
LONDON and NEW YORK, June 07, 2018 (GLOBE NEWSWIRE) — MeiraGTx Holdings plc (the “Company”), a vertically integrated, clinical stage gene therapy company, today announced the pricing of its initial public offering of 5,000,000 ordinary shares at a public offering price of $15.00 per share, for total gross proceeds of approximately $75.0 million, before underwriting discounts and commissions. In addition, the Company has granted the underwriters a 30-day option to purchase up to 750,000 additional ordinary shares from the Company at the initial public offering price, less the underwriting discounts and commissions. All of the ordinary shares are being offered by the Company. The Company’s ordinary shares are expected to begin trading on the Nasdaq Global Select Market on Friday, June 8, 2018 under the ticker symbol “MGTX.” The offering is expected to close on June 12, 2018, subject to customary closing conditions.
BofA Merrill Lynch, Barclays and Evercore ISI are acting as joint book-running managers for the offering. Chardan is acting as the lead manager for the offering.
A registration statement relating to the securities being sold in the offering has been declared effective by the Securities and Exchange Commission. This offering is being made only by means of a prospectus. Copies of the final prospectus relating to this offering may be obtained, when available, by contacting: BofA Merrill Lynch, NC1-004-03-43, 200 North College Street, 3rd Floor, Charlotte, NC 28255-0001, Attention: Prospectus Department, or by email at email@example.com; Barclays Capital Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 (telephone: (888) 603-5847 or email: Barclaysprospectus@broadridge.com); or Evercore ISI, Attention: Equity Capital Markets, 55 East 52nd Street, 36th Floor, New York, NY 10055, by phone at (888) 474-0200, or by email at firstname.lastname@example.org.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such state or jurisdiction.